Skip to main content

New coronavirus vaccine triggers immune response in early testing

A coronavirus vaccine developed by Oxford University and drug company AstraZeneca triggered an immune response in early trials, according to a study published on Monday, July 20

The vaccine produced strong immune responses in patients inoculated with both single- and two-dose versions of the vaccine. The promising results were first published in the scientific journal The Lancet.

Phase one of the trials took place with over 1,000 participants aged 18-55 years, all of whom had no history of coronavirus infection. While researchers stated that the two-dose vaccine produces a higher immune response, the single-dose vaccine is also useful. Both were deemed safe for human use, according to the study.

Given the moniker ChAdOx1 nCoV-19, the vaccine combines DNA from the coronavirus with an adapted adenovirus known to trigger illness in chimpanzees. 

However, the results do not prove that the vaccine will provide immunity from the coronavirus. Further trials are needed to determine if the vaccine prevents patients from catching the disease.

medical employee holding mask stylized image
Getty Images/Digital Trends Graphic

Researchers hope to begin trials in the United States in a few weeks. In June, Oxford University’s partner, AstraZeneca, announced it was striving to produce and distribute over 2 billion doses of the vaccine once available.

This news comes as researchers around the world race for a stable coronavirus vaccine. While Oxford University’s response is hopeful, other companies have also disclosed encouraging data on their vaccine research. In a 45-participant trial by drug development firm Moderna, another potential COVID-19 vaccine also generated an immune response.

Editors' Recommendations

Zoe Christen Jones
Zoe Christen Jones is a breaking news reporter. She covers news, digital culture, tech, and more. Previously, she was…
Google to ban ads from appearing next to coronavirus conspiracy theories
medical employee holding mask stylized image

Google will reportedly ban advertisements from running alongside debunked coronavirus conspiracy theories, starting in August.

Under the new policy, supervisors will be able to remove entire ads from articles, as well as ban all advertisements for websites that violate the new rule on multiple occasions, according to CNBC. Google had previously banned ads that made harmful claims about prevention and treatment of the coronavirus.

Read more
Moderna says early coronavirus vaccine results are promising
Cambridge Biotech Moderna Leads in Race For Coronavirus Vaccine

Biotechnology company Moderna has announced the first results from its Phase 1 trial of a vaccine for the coronavirus, showing that a small number of participants developed antibodies to the virus after treatment.

A Phase 1 trial is a small trial of typically around 10 to 20 people that tests whether a potential new treatment is safe and whether it shows signs of its intended effects. Moderna has released the results of the first 8 participants whose data has been analyzed, and they show that the vaccine appears to be safe and not have any serious negative effects.

Read more
The FDA has shut down a Bill Gates-backed coronavirus testing program
Bill Gates

The Food and Drug Administration (FDA) halted, at least temporarily, a Seattle-based at-home coronavirus testing program backed by Bill Gates.

“Please discontinue patient testing and return of diagnostic results to patients until proper authorization is obtained,” the FDA told the Seattle Coronavirus Assessment Network (SCAN) in a memo, according to The New York Times.

Read more